Bladder cancer is a heterogeneous malignancy and is responsible for approximately 3.2%
of new diagnoses of cancer per year (Sung et al., 2021). Fibroblast Growth Factor Receptors …

Despite recent advances, advanced-stage urothelial carcinoma (aUC) remains incurable,
with 5-year survival rates of approximately 10%. Platinum-based chemotherapy has a major …

Background Erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase
inhibitor, was shown to be clinically active and tolerable in patients with advanced urothelial …

Tyrosine Kinase Inhibitors - StatPearls - NCBI Bookshelf US flag An official website of the
United States government Here's how you know NIH NLM Logo Access keys NCBI Homepage …

Purpose: On 12 April 2019, erdafitinib gained the first FDA approval as the second-line
treatment for adult patients with locally advanced or metastatic urothelial cancer following …

The successful fabrication is reported of highly crystalline Co nanoparticles interconnected
with zeolitic imidazolate framework (ZIF-12)-based amorphous porous carbon using the …

Cisplatin-based chemotherapy is currently the first-line standard of care for patients with
metastatic urothelial cancer (mUC); however, up to 50% of patients are ineligible for …

Despite the significant improvements in the field of oncological treatments in recent
decades, and the advent of targeted therapies and immunotherapy, urothelial carcinoma of …

Background We aimed to provide regional data on clinical symptoms, medical resource
utilization (MRU), and risk factors for increased MRU in hospitalized respiratory syncytial …

In recent years, increasing research attention has been directed to structurally diverse
pyrazole derivatives, many of which have become commercially available drugs with …